291 related articles for article (PubMed ID: 23236438)
1. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms.
Thomas EC; Gunter JH; Webster JA; Schieber NL; Oorschot V; Parton RG; Whitehead JP
PLoS One; 2012; 7(12):e51096. PubMed ID: 23236438
[TBL] [Abstract][Full Text] [Related]
2. IMPDH dysregulation in disease: a mini review.
Burrell AL; Kollman JM
Biochem Soc Trans; 2022 Feb; 50(1):71-82. PubMed ID: 35191957
[TBL] [Abstract][Full Text] [Related]
3. A regulatory role of the Bateman domain of IMP dehydrogenase in adenylate nucleotide biosynthesis.
Pimkin M; Pimkina J; Markham GD
J Biol Chem; 2009 Mar; 284(12):7960-9. PubMed ID: 19153081
[TBL] [Abstract][Full Text] [Related]
4. The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover.
Pimkin M; Markham GD
Mol Microbiol; 2008 Apr; 68(2):342-59. PubMed ID: 18312263
[TBL] [Abstract][Full Text] [Related]
5. Terminal Peptide Extensions Augment the Retinal IMPDH1 Catalytic Activity and Attenuate the ATP-induced Fibrillation Events.
Andashti B; Yazdanparast R; Motahar M; Barzegari E; Galehdari H
Cell Biochem Biophys; 2021 Jun; 79(2):221-229. PubMed ID: 33733369
[TBL] [Abstract][Full Text] [Related]
6. Insight into the role of the Bateman domain at the molecular and physiological levels through engineered IMP dehydrogenases.
Gedeon A; Ayoub N; Brûlé S; Raynal B; Karimova G; Gelin M; Mechaly A; Haouz A; Labesse G; Munier-Lehmann H
Protein Sci; 2023 Aug; 32(8):e4703. PubMed ID: 37338125
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Terminal Peptide Extensions of Retinal Inosine 5´Monophosphate Dehydrogenase 1 Isoforms on their DNA-binding Activities.
Nabi Afjadi M; Yazdanparast R; Barzegari E
Protein J; 2024 Jun; 43(3):592-602. PubMed ID: 38733555
[TBL] [Abstract][Full Text] [Related]
8. Neurodevelopmental disorder mutations in the purine biosynthetic enzyme IMPDH2 disrupt its allosteric regulation.
O'Neill AG; Burrell AL; Zech M; Elpeleg O; Harel T; Edvardson S; Mor-Shaked H; Rippert AL; Nomakuchi T; Izumi K; Kollman JM
J Biol Chem; 2023 Aug; 299(8):105012. PubMed ID: 37414152
[TBL] [Abstract][Full Text] [Related]
9. IMPDH1 retinal variants control filament architecture to tune allosteric regulation.
Burrell AL; Nie C; Said M; Simonet JC; Fernández-Justel D; Johnson MC; Quispe J; Buey RM; Peterson JR; Kollman JM
Nat Struct Mol Biol; 2022 Jan; 29(1):47-58. PubMed ID: 35013599
[TBL] [Abstract][Full Text] [Related]
10. Inosine monophosphate dehydrogenase type1 sustains tumor growth in hepatocellular carcinoma.
Jia X; Liu Y; Cheng Y; Wang Y; Kang H; Ma Z; Chen K
J Clin Lab Anal; 2022 May; 36(5):e24416. PubMed ID: 35403278
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.
Wu TY; Peng Y; Pelleymounter LL; Moon I; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM
Br J Pharmacol; 2010 Dec; 161(7):1584-98. PubMed ID: 20718729
[TBL] [Abstract][Full Text] [Related]
12. IMP dehydrogenase type 1 associates with polyribosomes translating rhodopsin mRNA.
Mortimer SE; Xu D; McGrew D; Hamaguchi N; Lim HC; Bowne SJ; Daiger SP; Hedstrom L
J Biol Chem; 2008 Dec; 283(52):36354-60. PubMed ID: 18974094
[TBL] [Abstract][Full Text] [Related]
13. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.
Bowne SJ; Sullivan LS; Mortimer SE; Hedstrom L; Zhu J; Spellicy CJ; Gire AI; Hughbanks-Wheaton D; Birch DG; Lewis RA; Heckenlively JR; Daiger SP
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):34-42. PubMed ID: 16384941
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa.
Bowne SJ; Sullivan LS; Blanton SH; Cepko CL; Blackshaw S; Birch DG; Hughbanks-Wheaton D; Heckenlively JR; Daiger SP
Hum Mol Genet; 2002 Mar; 11(5):559-68. PubMed ID: 11875050
[TBL] [Abstract][Full Text] [Related]
15. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa.
Aherne A; Kennan A; Kenna PF; McNally N; Lloyd DG; Alberts IL; Kiang AS; Humphries MM; Ayuso C; Engel PC; Gu JJ; Mitchell BS; Farrar GJ; Humphries P
Hum Mol Genet; 2004 Mar; 13(6):641-50. PubMed ID: 14981049
[TBL] [Abstract][Full Text] [Related]
16. Inosine-5'-monophosphate dehydrogenase is required for mitogenic competence of transformed pancreatic beta cells.
Metz S; Holland S; Johnson L; Espling E; Rabaglia M; Segu V; Brockenbrough JS; Tran PO
Endocrinology; 2001 Jan; 142(1):193-204. PubMed ID: 11145582
[TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice.
Gu JJ; Tolin AK; Jain J; Huang H; Santiago L; Mitchell BS
Mol Cell Biol; 2003 Sep; 23(18):6702-12. PubMed ID: 12944494
[TBL] [Abstract][Full Text] [Related]
18. LncRNA UCA1 Participates in De Novo Synthesis of Guanine Nucleotides in Bladder Cancer by Recruiting TWIST1 to Increase IMPDH1/2.
Liu SS; Li JS; Xue M; Wu WJ; Li X; Chen W
Int J Biol Sci; 2023; 19(8):2599-2612. PubMed ID: 37215997
[TBL] [Abstract][Full Text] [Related]
19. IMPDH2 genetic polymorphism: a promoter single-nucleotide polymorphism disrupts a cyclic adenosine monophosphate responsive element.
Garat A; Cauffiez C; Hamdan-Khalil R; Glowacki F; Devos A; Leclerc J; Lionet A; Allorge D; Lo-Guidice JM; Broly F
Genet Test Mol Biomarkers; 2009 Dec; 13(6):841-7. PubMed ID: 19810816
[TBL] [Abstract][Full Text] [Related]
20. Guanine nucleotide binding to the Bateman domain mediates the allosteric inhibition of eukaryotic IMP dehydrogenases.
Buey RM; Ledesma-Amaro R; Velázquez-Campoy A; Balsera M; Chagoyen M; de Pereda JM; Revuelta JL
Nat Commun; 2015 Nov; 6():8923. PubMed ID: 26558346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
